<DOC>
	<DOCNO>NCT01089504</DOCNO>
	<brief_summary>The treatment infant medication seizure stop variable . No one know continue treatment phenobarbital several month helpful harmful . This clinical trial design help answer question provide data help determine standard care child .</brief_summary>
	<brief_title>Prophylactic Phenobarbital After Neonatal Seizures</brief_title>
	<detailed_description>The treatment infant antiepileptic medication resolution neonatal seizures highly variable controversial . Infants commonly treat phenobarbital seizure resolve prevent recurrence . Data support practice lack animal model suggest neonatal brain vulnerable repeated seizure . Yet exposure develop brain phenobarbital prolong period may deleterious consequence . We propose multi-center , randomize , clinical trial ( RCT ) determine continue treatment phenobarbital reduces seizure recurrence without adversely affect neurodevelopmental outcome infant ' outcome improve prophylactic medication give . We identify infant seizure begin first week resolve within 7 day randomize receive phenobarbital placebo daily four month . Via visit frequent telephone contact first six month , determine rate seizure recurrence . The primary outcome , neurodevelopmental status , assess 18-22 month use Bayley Scales Infant Development . Additional subgroup analysis plan determine contribution seizure etiology outcome predictive value initial EEG classification . The trial conduct 18 - 20 site , choose experience proven track record enrollment retention specific population . The trial coordinate Clinical Trials Coordination Center University Rochester overseen Steering Committee compose experienced trialists represent neonatology pediatric neurology , biostatistics , clinical trial administration . Extrapolation result RCT phenobarbital prophylaxis febrile seizures child suggest phenobarbital may adversely affect brain development may ineffective preventing seizure . Based previous RCT result near universal change practice ( elimination prolong use phenobarbital simple febrile seizure ) , anticipate data generate may similar impact standard care infant neonatal seizure .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Phenobarbital</mesh_term>
	<criteria>Birth &gt; 34 week ' gestation Neonatal seizure ( clinical , electrographic ) , onset first 120 hour birth resolution within 7 day onset Parental informed consent Birth &lt; 34 week ' gestation If attending neonatologist attribute seizure solely transient abnormality , easily correctable unlikely recur ( eg , transient electrolyte abnormality ) . If attending neonatologist contact , site PI ask review available information judge whether infant eligible . If infant diagnose strong suspicion inborn error metabolism , significant brain malformation , microcephaly ( &lt; 3 % ile ) , chromosomal abnormality , absence seizure , know independently associate increase likelihood cognitive impairment If infant diagnose intrauterine viral infection If infant expect survive discharge</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>2 Weeks</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>phenobarbital</keyword>
	<keyword>neonate</keyword>
	<keyword>antiepileptic drug</keyword>
	<keyword>neurodevelopmental outcome</keyword>
	<keyword>seizure</keyword>
</DOC>